BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2730 related articles for article (PubMed ID: 17916108)

  • 1. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
    Kane SV; Sandborn WJ; Rufo PA; Zholudev A; Boone J; Lyerly D; Camilleri M; Hanauer SB
    Am J Gastroenterol; 2003 Jun; 98(6):1309-14. PubMed ID: 12818275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.
    Sugi K; Saitoh O; Hirata I; Katsu K
    Am J Gastroenterol; 1996 May; 91(5):927-34. PubMed ID: 8633583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between fecal lactoferrin and inflammatory bowel disease.
    Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
    Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.
    Kayazawa M; Saitoh O; Kojima K; Nakagawa K; Tanaka S; Tabata K; Matsuse R; Uchida K; Hoshimoto M; Hirata I; Katsu K
    Am J Gastroenterol; 2002 Feb; 97(2):360-9. PubMed ID: 11866274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.
    Langhorst J; Junge A; Rueffer A; Wehkamp J; Foell D; Michalsen A; Musial F; Dobos GJ
    Am J Gastroenterol; 2009 Feb; 104(2):404-10. PubMed ID: 19174795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial.
    Langhorst J; Boone J; Lauche R; Rueffer A; Dobos G
    J Crohns Colitis; 2016 Jul; 10(7):786-94. PubMed ID: 26874351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal markers: calprotectin and lactoferrin.
    Abraham BP; Kane S
    Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin.
    Schröder O; Naumann M; Shastri Y; Povse N; Stein J
    Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease.
    Walker TR; Land ML; Kartashov A; Saslowsky TM; Lyerly DM; Boone JH; Rufo PA
    J Pediatr Gastroenterol Nutr; 2007 Apr; 44(4):414-22. PubMed ID: 17414136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
    Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 137.